Mature B-cell lymphomas in adolescents and young adults.
DLBCL
PMBCL
adolescent
mature B cell lymphoma
young adult
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
17
06
2023
revised:
20
07
2023
accepted:
21
07
2023
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Pediatric non-Hodgkin lymphoma includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the US, compared to >60,000 cases of adult NHL annually. Improvements in survival in pediatric and adolescent mature B cell NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes through dose escalation of chemotherapy and, more recently, targeted therapy with rituximab. Pediatric dose-intense strategies carry risks of long-term consequences, but treatment failure is nearly universally fatal. By comparison, adult mature B cell lymphoma is typically less aggressive and treated with less intense chemotherapy. Optimizing therapy for adolescents and young adults remains a major challenge that requires creative solutions, including engineering study groups to combine biologically comparable adult and pediatric populations and developing effective salvage strategies that will ultimately be required for investigations of front-line dose reduction. In this review, we discuss challenges and opportunities for improving outcomes for adolescents and young adults with high-grade mature B cell lymphomas, diffuse large B cell lymphoma, and primary mediastinal B cell lymphoma.
Identifiants
pubmed: 38024628
doi: 10.1002/jha2.783
pii: JHA2783
pmc: PMC10660408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
912-920Informations de copyright
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
CEA: Advisory board, Sobi. Research support, Genentech. Other authors have no conflict of interest to disclose.
Références
Nat Med. 2015 Aug;21(8):922-6
pubmed: 26193343
N Engl J Med. 2022 Dec 15;387(24):2220-2231
pubmed: 36507690
Lancet. 2022 Jun 18;399(10343):2294-2308
pubmed: 35717989
Blood. 2018 Aug 23;132(8):782-790
pubmed: 29976557
Lancet. 2021 Sep 25;398(10306):1157-1169
pubmed: 34508654
Blood. 2007 Apr 1;109(7):2773-80
pubmed: 17132719
J Clin Oncol. 2021 Apr 20;39(12):1329-1338
pubmed: 33555941
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Clin Oncol. 2019 May 20;37(15):1285-1295
pubmed: 30901302
Blood. 2005 Feb 1;105(3):948-58
pubmed: 15486066
Haematologica. 2011 Dec;96(12):1888-90
pubmed: 21859735
J Clin Oncol. 2019 Jan 20;37(3):202-212
pubmed: 30523719
Blood. 2012 Apr 19;119(16):3757-66
pubmed: 22374697
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Haematologica. 2021 Oct 01;106(10):2774-2778
pubmed: 34233448
Blood. 2014 Mar 27;123(13):2062-5
pubmed: 24497532
N Engl J Med. 2020 Jun 4;382(23):2207-2219
pubmed: 32492302
N Engl J Med. 2022 Feb 17;386(7):629-639
pubmed: 34904798
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Br J Haematol. 2008 Jun;141(6):840-7
pubmed: 18371107
Blood Adv. 2020 Aug 25;4(16):4007-4019
pubmed: 32841337
Haematologica. 2016 Dec;101(12):1581-1591
pubmed: 27515251
Blood Adv. 2023 Feb 28;7(4):602-610
pubmed: 36541957
Blood. 2015 Oct 15;126(16):1893-901
pubmed: 26232170
J Clin Oncol. 2017 Aug 1;35(22):2473-2481
pubmed: 28426350
Blood. 2023 May 18;141(20):2493-2507
pubmed: 36302166
J Clin Oncol. 2017 Nov 1;35(31):3538-3546
pubmed: 28862883
Cancer Cell. 2020 Apr 13;37(4):551-568.e14
pubmed: 32289277
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Br J Haematol. 2020 Jun;189(5):826-843
pubmed: 32141616
Br J Haematol. 2014 Nov;167(3):394-401
pubmed: 25066629
Blood. 2020 Apr 2;135(14):1124-1132
pubmed: 31961927
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Cancer Cell. 2021 Dec 13;39(12):1643-1653.e3
pubmed: 34739844
Virchows Arch. 2023 Jan;482(1):193-205
pubmed: 36057749
Blood. 2010 Sep 23;116(12):2040-5
pubmed: 20548096
J Clin Oncol. 2023 Apr 20;41(12):2238-2247
pubmed: 36548927
J Clin Oncol. 2019 Dec 1;37(34):3291-3299
pubmed: 31609651
N Engl J Med. 2022 Jan 27;386(4):351-363
pubmed: 34904799
Br J Haematol. 2022 Feb;196(4):849-863
pubmed: 34866182
N Engl J Med. 2002 Jan 24;346(4):235-42
pubmed: 11807147
J Clin Oncol. 2021 Apr 20;39(12):1317-1328
pubmed: 33621109
Ann Oncol. 2018 Mar 1;29(3):707-714
pubmed: 29253068
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Lancet. 2011 Nov 26;378(9806):1858-67
pubmed: 22118442
Lancet Haematol. 2020 Jul;7(7):e511-e522
pubmed: 32589977
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Lancet Oncol. 2021 Jun;22(6):790-800
pubmed: 33989558
Blood. 2017 Apr 20;129(16):2328-2330
pubmed: 28264798
Haematologica. 2021 Sep 01;106(9):2417-2426
pubmed: 34196165
Br J Haematol. 2019 Jun;185(6):1071-1085
pubmed: 30613948
Pediatr Blood Cancer. 2019 Sep;66(9):e27873
pubmed: 31207026
J Clin Oncol. 2021 Jun 20;39(18):1959-1970
pubmed: 33739857
Blood. 2018 Jul 26;132(4):369-375
pubmed: 29895666
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Br J Haematol. 2018 Sep;182(6):859-869
pubmed: 29984828
J Clin Oncol. 2017 Nov 1;35(31):3529-3537
pubmed: 28796588